Treatment of cancer with combinations of immunoregulatory agents
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsStephen Willingham, Doris Po Yi Ho, Kelly Marie McKenna, Irving L. Weissman, Jens-Peter Volkmer, Mark P. Chao, Ravindra Majeti, Melissa N. McCracken
Life of this patent
Estimating the term…
Abstract
Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of immunoregulatory agents. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.
Claims18
A method of targeting human cancer cells for immunodepletion, by human phagocytic cells, the method comprising:
- contacting, in the presence of the human phagocytic cells, a population of cells comprising the targeted cancer cells with a combination of (i) an anti-CD47 antibody;
- and (ii) an antibody that antagonizes an immune inhibitory molecule,
- wherein the combination is administered in a dose that achieves immunodepletion of the targeted cancer cells;
- thereby immunodepleting the targeted cancer cells by the phagocytic cells in a dose.
2-5. (canceled)
7-9. (canceled)
14-15. (canceled)
18-19. (canceled)
21-22. (canceled)
Dependencies are inferred from the claim text.